Overview

Ipilimumab for Head and Neck Cancer Patients

Status:
Unknown status
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to surgical resection, and the immune system response to treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Providence Health & Services
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Ipilimumab